Study guide
20.1 Sepsis-3 Definitions & the Sepsis Six
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
20.1 Sepsis-3 Definitions & the Sepsis Six
Key Takeaways Explain This Topic AI
Septic shock is defined as sepsis requiring vasopressors to maintain a mean arterial pressure of 65 mmHg or more with a lactate above 2 mmol/L despite adequate fluid resuscitation.
The Sepsis Six comprises oxygen, blood cultures, intravenous antibiotics, intravenous fluids, lactate measurement and urine output monitoring, delivered within one hour.
Blood cultures should be taken before antibiotics wherever this does not delay treatment, because they remain the key to organism-directed therapy.
Last updated: September 2026
Severe bacterial infections and systemic dysregulated inflammatory states represent core emergencies frequently tested in MRCP(UK) Part 1. Candidates must possess detailed command of consensus definitions (Sepsis-3), validated bedside risk tools, time-critical resuscitation protocols (the Sepsis Six), empirical antimicrobial choices stratified by host vulnerability, cerebrospinal fluid (CSF) cytochemical interpretation, and the toxin-mediated pathophysiology of toxic shock syndromes.
1. Sepsis-3 Definitions & Pathophysiological Principles
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) replaced the historical Systemic Inflammatory Response Syndrome (SIRS) criteria, which lacked both sensitivity and specificity for life-threatening pathology.
Core Consensus Definitions
Sepsis: Defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. In clinical practice, organ dysfunction is operationalised as an acute change in total Sequential Organ Failure Assessment (SOFA) score ≥ 2 points \ge 2\text{ points} ≥ 2 points attributable to the infectious insult. A baseline SOFA score is assumed to be zero in patients without pre-existing organ impairment. An acute increase of ≥ 2 points \ge 2\text{ points} ≥ 2 points reflects an overall in-hospital mortality excess of approximately 10 % 10\% 10% .
Quick SOFA (qSOFA): A simplified bedside screening tool designed to identify patients outside the intensive care unit (ICU) with suspected infection who are at heightened risk of prolonged ICU stay or in-hospital death. It does not define sepsis itself, but flags high risk when ≥ 2 \ge 2 ≥ 2 of the following 3 criteria (HAT) are met:
- H — Hypotension: Systolic blood pressure ≤ 100 mmHg \le 100\text{ mmHg} ≤ 100 mmHg
- A — Altered mental status: Glasgow Coma Scale (GCS) score < 15 < 15 < 15
- T — Tachypnoea: Respiratory rate ≥ 22 breaths/min \ge 22\text{ breaths/min} ≥ 22 breaths/min
Septic Shock: A subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality ( > 40 % > 40\% > 40% ). Clinically identified by patients with sepsis who exhibit both :
Persistent hypotension requiring vasopressors to maintain a Mean Arterial Pressure (MAP) ≥ 65 mmHg \ge 65\text{ mmHg} ≥ 65 mmHg , AND
Serum lactate > 2.0 mmol/L > 2.0\text{ mmol/L} > 2.0 mmol/L ( 18 mg/dL 18\text{ mg/dL} 18 mg/dL ) despite adequate intravascular volume resuscitation.
Pathophysiological Cascade
Infection triggers recognition of pathogen-associated molecular patterns (PAMPs, such as Gram-negative lipopolysaccharide/endotoxin and Gram-positive peptidoglycan/lipoteichoic acid) by host pattern recognition receptors, particularly Toll-like receptor 4 (TLR-4) on monocytes and macrophages. This initiates massive transcription of pro-inflammatory cytokines: tumour necrosis factor-alpha (TNF- α \alpha α ), interleukin-1 (IL-1), and interleukin-6 (IL-6).
This cytokine storm disrupts the endothelial glycocalyx, activates inducible nitric oxide synthase (iNOS) with profound systemic vasodilation, causes widespread capillary leak, and induces tissue factor expression on endothelial cells. Disseminated microvascular thrombosis ensues alongside impaired endogenous fibrinolysis (driven by elevated plasminogen activator inhibitor-1 [PAI-1]). Tissue dysoxia occurs not merely from hypoperfusion, but from direct mitochondrial dysfunction ('cellular hibernation'), explaining persistent hyperlactataemia even when macrovascular haemodynamics appear restored.
2. The Sepsis Six Care Bundle & Acute Resuscitation
The UK Sepsis Trust and Surviving Sepsis Campaign mandate that the Sepsis Six bundle be initiated and fully delivered within 1 hour of recognition of severe sepsis or septic shock. This rapid operational protocol halves mortality when delivered comprehensively.
Operational Direction Bundle Component Clinical Standard & Physiological Target
IN (Deliver) 1. Intravenous Fluid Resuscitation Administer an initial bolus of 30 mL/kg 30\text{ mL/kg} 30 mL/kg of balanced crystalloid (e.g., Hartmann's solution or Plasma-Lyte) within the first 3 hours. Balanced crystalloids reduce hyperchloraemic metabolic acidosis and acute kidney injury compared to 0.9 % 0.9\% 0.9% normal saline. Re-assess volume responsiveness via dynamic parameters (capillary refill time, passive leg raise, stroke volume variation).
IN (Deliver) 2. Intravenous Broad-Spectrum Antibiotics Administer maximal therapeutic doses of broad-spectrum antimicrobials within 60 minutes of identification, targeted to the presumed focus and local antimicrobial resistance patterns. Each hour of delay in septic shock is associated with an incremental 7.6 % 7.6\% 7.6% reduction in survival.
IN (Deliver) 3. Oxygen Therapy Titrate supplemental oxygen to maintain target oxygen saturations of 94 – 98 % 94\text{–}98\% 94 – 98% in non-hypercapnic patients, or 88 – 92 % 88\text{–}92\% 88 – 92% in patients at risk of hypercapnic respiratory failure (e.g., severe COPD).
OUT (Obtain) 4. Blood Cultures Inoculate at least two sets of blood cultures (aerobic and anaerobic bottles) prior to antibiotic administration , provided this does not cause significant delay ( > 45 minutes > 45\text{ minutes} > 45 minutes ). Obtain additional cultures (sputum, urine, wound, CSF) as indicated.
OUT (Obtain) 5. Blood Lactate Measurement Measure baseline venous or arterial blood lactate. A level > 2 mmol/L > 2\text{ mmol/L} > 2 mmol/L denotes cellular hypoperfusion; > 4 mmol/L > 4\text{ mmol/L} > 4 mmol/L indicates critical metabolic failure. Serial lactate measurements every 2–4 hours guide resuscitation (aiming for ≥ 20 % \ge 20\% ≥ 20% clearance every 2 hours).
OUT (Obtain) 6. Strict Urine Output Monitoring Insert an indwelling Foley urinary catheter with a urometer to monitor hourly urine output. The physiological threshold for renal hypoperfusion is < 0.5 mL/kg/h < 0.5\text{ mL/kg/h} < 0.5 mL/kg/h for two consecutive hours.
Advanced Vasoactive Support
When fluid resuscitation fails to restore a MAP ≥ 65 mmHg \ge 65\text{ mmHg} ≥ 65 mmHg , vasopressor therapy must be initiated without delay via a central venous catheter (or temporarily via an established wide-bore peripheral cannula):
First-line Vasopressor: Noradrenaline (norepinephrine) is the agent of choice. It acts predominantly as an α 1 \alpha_1 α 1 -adrenergic agonist with potent vasoconstrictor effects, supported by modest β 1 \beta_1 β 1 -inotropic action, avoiding the profound tachycardia associated with adrenaline or dopamine.
Second-line Vasopressor: Vasopressin (arginine vasopressin) titrated up to 0.03 units/min 0.03\text{ units/min} 0.03 units/min to reduce noradrenaline dosage requirements and correct endogenous vasopressin deficiency.
Inotropic Support: Dobutamine is added when myocardial dysfunction persists (elevated cardiac filling pressures and low cardiac output) despite adequate MAP.
Refractory Shock: Intravenous hydrocortisone ( 200 mg/day 200\text{ mg/day} 200 mg/day administered as 50 mg 50\text{ mg} 50 mg 6-hourly or as a continuous infusion) is indicated only in septic shock refractory to fluid resuscitation and high-dose vasopressor therapy.